2 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
Follow Oncomatryx Biopharma S.L.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma OMTX705, Nab-paclitaxel + Gemcitabine, Tislelizumab (i.v. 200mg) - Pancreatic Adenocarcinoma Metastatic | Phase 1 | Recruiting | Oncomatryx Biopharma S.L. | 69 | 2025-10-28 | 2026-10-15 |
| Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors. OMTX705, Pembrolizumab, Tislelizumab (BGB-A317) - Advanced Solid Tumor | Phase 1 | Recruiting | Oncomatryx Biopharma S.L. | 150 | 2022-10-20 | 2025-11-25 |
tislelizumab (2) · 130-nm albumin-bound paclitaxel (1) · Gemcitabine (1) · Patents as Topic (1) · pembrolizumab (1)
Spain (2) · United States (2)
2025 (1)